Reversal of resistance of multidrug resistant MCF/Dox cell line to doxorubicin by a benflumetol derivative LY980503

Chinese Journal of Pharmacology and Toxicology

Volumn 16, Issue 3, 2002, Pages 211-215

  Wu, Da Long ^a   Lu, Huan Zhang ^a   Huang, Feng ^a   Yin, Li Xin ^a   Wan, Yong Ling ^a   Guo, Jun Hua ^a   Wu, De Zheng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Benflumetol; Breast neoplasms; Cell line, MCF 7; Drug resistance, multiple; Human

Indexed keywords

BENFLUMETOL; DOXORUBICIN; DRUG DERIVATIVE; LY 980503; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL LINE; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG STRUCTURE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

EID: 0036297864     PISSN: 10003002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Recent progress in P-glycoprotein research
2. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells
3. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patient with relapsed or refractory acute leukemia
4. Quercetin potentiates the effect of adriamycin in a multidrug resistance MCF-7 human breast cancer cell line: P-glycoprotein as a possible target
5. Interaction of tamoxifen with the multidrug resistance P-glyeoprotein
6. Staurosporine analogues? Pharmacological toys or useful antitumor agents?
7. Triphenylethylenes: A new class of protein kinase C inhibitors